![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Casirivimab and Imdevimab Combination Provides Long-Term
Protection Against COVID-19 - phase 3 study in preventing
COVID in household contacts of infected individuals
|
|
|
CROI 2022 Feb 11-16
Meagan P. O'Brien, MD
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
On behalf of the Regeneron and CoVPN/NIAID COVID-19
Phase 3 Prevention Trial Team
![0217221](../images/021722/021722-4/0217221.gif)
![0217222](../images/021722/021722-4/0217222.gif)
![0217223](../images/021722/021722-4/0217223.gif)
![0217224](../images/021722/021722-4/0217224.gif)
![0217225](../images/021722/021722-4/0217225.gif)
![0217226](../images/021722/021722-4/0217226.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|